Rhythm Pharmaceuticals, Inc.
RYTM
$68.11
$1.932.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.82% | 25.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.82% | 25.80% | |||
| Cost of Revenue | -3.67% | -1.07% | |||
| Gross Profit | -23.62% | 29.30% | |||
| SG&A Expenses | 2.51% | 7.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.06% | 7.71% | |||
| Operating Income | -13.94% | 5.99% | |||
| Income Before Tax | -13.91% | 1.37% | |||
| Income Tax Expenses | 188.89% | 73.84% | |||
| Earnings from Continuing Operations | -14.34% | 0.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.34% | 0.80% | |||
| EBIT | -13.94% | 5.99% | |||
| EBITDA | -14.07% | 6.04% | |||
| EPS Basic | -11.22% | 1.36% | |||
| Normalized Basic EPS | -11.27% | 1.96% | |||
| EPS Diluted | -11.22% | 1.36% | |||
| Normalized Diluted EPS | -11.27% | 1.96% | |||
| Average Basic Shares Outstanding | 2.37% | 0.61% | |||
| Average Diluted Shares Outstanding | 2.37% | 0.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||